Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.60 |
| ▸ | MEN1 | O00255 | 3/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.60 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.58 |
| ▸ | DHODH | Q02127 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 2/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 2/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | NPY1R | P25929 | 1/20 | 0.50 |
| ▸ | NPY2R | P49146 | 1/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30526578 | 1.00 | MAPT (0.60) | MAPTMEN1KMT2AALDH1A1SIGMAR1 | |
| SCHEMBL30051993 | 0.86 | MAPT (0.71) | MAPTMEN1KMT2AALDH1A1SIGMAR1 | |
| SCHEMBL3440627 | 0.86 | ALDH1A1 (0.59) | MAPTMEN1KMT2AALDH1A1SIGMAR1 | |
| SCHEMBL4808346 | 0.85 | ALDH1A1 (0.56) | MAPTMEN1KMT2AALDH1A1HPGD | |
| SCHEMBL1284518 | 0.84 | ALDH1A1 (0.64) | MAPTMEN1KMT2AALDH1A1HPGD | |
| SCHEMBL18324579 | 0.83 | SIGMAR1 (0.59) | MAPTMEN1KMT2AALDH1A1SIGMAR1 | |
| SCHEMBL31236186 | 0.82 | ALDH1A1 (0.62) | MAPTMEN1KMT2AALDH1A1HPGD | |
| SCHEMBL31236185 | 0.82 | ALDH1A1 (0.62) | MAPTMEN1KMT2AALDH1A1HPGD | |
| SCHEMBL29572629 | 0.82 | ALDH1A1 (0.62) | MAPTMEN1KMT2AALDH1A1HPGD | |
| SCHEMBL28724549 | 0.82 | ALDH1A1 (0.62) | MAPTMEN1KMT2AALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025137606-A1 | (HETERO)ARYL NRF2 PROTEIN DEGRADERS | GANYMEDE ONCOLOGY, INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| WO-2025111547-A1 | 2,3-DIHYDROPYROLLOPYRIDINE CARBOXAMIDE COMPOUNDS AND METHODS OF USE THEREOF | RGENTA THERAPEUTICS, INC. (US) | 2025-05-30 | — | — | WO | disclosed |
| US-20250026766-A1 | Thiazolopyridyl Amide Derivatives as DNA Polymerase Theta Inhibitors | BEIGENE, LTD. (KY) | 2025-01-23 | — | — | US | disclosed |
| WO-2023134708-A1 | THIAZOLOPYRIDYL AMIDE DERIVATIVES AS DNA POLYMERASE THETA INHIBITORS | BEIGENE , LTD. (KY) | 2023-07-20 | — | — | WO | disclosed |
| WO-2021041237-A1 | THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS | Terns, Inc. (US) | 2021-03-04 | — | — | WO | disclosed |
| CN-108147972-B | Preparation method of vipatavir intermediate and analogue thereof | 成都西岭源药业有限公司 | 2020-07-10 | — | — | CN | disclosed |
| EP-2874632-B1 | TRIAZINE COMPOUND HAVING PI3K-ALPHA AND MTOR INHIBITING ACTIVITY | SPHAERA PHARMA PTE LTD (SG) | 2020-06-17 | — | — | EP | disclosed |
| US-9630958-B2 | Triazine compounds | SPHAERA PHARMA PTE. LTD. (SG) | 2017-04-25 | — | — | US | disclosed |
| US-20150197515-A1 | NOVEL TRIAZINE COMPOUNDS | SPHAERA PHARMA PTE. LTD. (SG) | 2015-07-16 | — | — | US | disclosed |
| CN-103787895-A | Production process for synthesizing 4-bromo-2-methylaniline | ANHUI HUARUN PAINTS CO LTD | 2014-05-14 | — | — | CN | disclosed |
| EP-1127060-A1 | HYDROBORONATION PROCESS | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2001-08-29 | — | — | EP | disclosed |
| EP-1090907-A1 | A process for the production of amides from amines | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2001-04-11 | — | — | EP | disclosed |
| US-6215024-B1 | ACYLATING AMINE WITH ACETIC, PROPIONIC AND/OR BUTYRIC ACID IN PRESENCE OF METAL ION EXCHANGED MONTMORILLIONITE CLAY CATALYST IN SOLVENT; AMIDATION | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2001-04-10 | — | — | US | disclosed |
| WO-2001017943-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | TARGACEPT, INC. (US) | 2001-03-15 | — | — | WO | disclosed |
| WO-2000063207-A1 | PESTICIDAL INDAZOLE OR BENZOTRIAZOLE DERIVATIVES | SYNGENTA LIMITED (GB) | 2000-10-26 | — | — | WO | disclosed |
| WO-2000027853-A1 | HYDROBORONATION PROCESS | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2000-05-18 | — | — | WO | disclosed |
| WO-1993012795-A1 | QUINAZOLIN-4(3H)-ONE DERIVATIVES AS ANTICOCCIDIAL AGENTS | GLAZER EDWARD A (US) | 1993-07-08 | — | — | WO | disclosed |
| US-4920224-A | CHEMICAL INTERMEDIATES | PFIZER INC. (US) | 1990-04-24 | — | — | US | disclosed |
| US-4849518-A | ANTIPROTOZOA IN POULTRY | PFIZER INC. (US) | 1989-07-18 | — | — | US | disclosed |
| US-4762838-A | Quinazolin-4(3H)-one derivatives as anticoccidial agents | PFIZER INC. (US) | 1988-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250026766-A1 | Thiazolopyridyl Amide Derivatives as DNA Polymerase Theta Inhibitors | POLQ, POLK, POLI | MAPT 544/4885MEN1 3950/4885KMT2A 849/4885 |
| US-20150197515-A1 | NOVEL TRIAZINE COMPOUNDS | MTOR, PIK3R5, PIK3R2 | MAPT 2037/4885MEN1 3314/4885KMT2A 2996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.